In tumor cells, activation of oncogenes (such as Ras, Src) or dysfunction of tumor suppressor genes (such as p53) frequently leads to significant alterations in TDEV release and cargo composition through modulation of these pathways. The gene discussed is TP53; the disease is neoplasm.